Therapeutic proteins have a propensity for aggregation during manufacturing, shipping, and
storage. The presence of aggregates in protein drug products can induce adverse immune …

Antibodies are proteins that recognize the molecular surfaces of potentially noxious
molecules to mount an adaptive immune response or, in the case of autoimmune diseases …

The use of monoclonal antibodies as therapeutics requires optimizing several of their key
attributes. These include binding affinity and specificity, folding stability, solubility …

Therapeutic antibodies and antibody derivatives comprise the majority of today's
biotherapeutics. Routine methods to generate novel antibodies, such as immunization and …

For mAbs to be viable therapeutics, they must be formulated to have low viscosity, be
chemically stable, and have normal in vivo clearance rates. We explored these properties by …

Natural enzymes are delicate biomolecules possessing only marginal thermodynamic
stability. Poorly stable, misfolded, and aggregated proteins lead to huge economic losses in …

Solubility of recombinant proteins (ie, the extent of soluble versus insoluble expression in
heterogeneous hosts) is the first checkpoint criterion for determining recombinant protein …

The widespread use of monoclonal antibodies for therapeutic applications has led to intense
interest in optimizing several of their natural properties (affinity, specificity, stability, solubility …

Increasing attention has been paid to developability assessment with the understanding that
thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid …

Protein aggregation is a phenomenon that has attracted considerable attention within the
pharmaceutical industry from both a developability standpoint (to ensure stability of protein …